Toll-like receptor 4 (TLR4)
toll-like receptor 4 (TLR4) is a pattern recognition receptor belonging to the toll-like receptor (TLR) family, encoded by the TLR4 gene.
toll-like receptor 4 (TLR4) is a pattern recognition receptor belonging to the toll-like receptor (TLR) family, encoded by the TLR4 gene. It is a transmembrane glycoprotein constitutively expressed on the surface of innate immune cells — including monocytes, macrophages, dendritic cells, neutrophils, and microglia — as well as on a variety of non-immune cell types such as hepatic stellate cells and neurons. TLR4 is best characterized as the primary sensor for lipopolysaccharide (LPS), a structural component of gram-negative bacterial cell walls, but it also recognizes endogenous danger signals (damage-associated molecular patterns, or DAMPs) such as high-mobility group box 1 protein (high mobility group box 1 (HMGB1)) and lumican. Upon ligand binding, TLR4 recruits the adapter proteins TIRAP/MAL and TRAM, which facilitate recruitment of myeloid differentiation primary response 88 (MyD88) and TRIF, initiating downstream signaling cascades that culminate in the activation of nuclear factor kappa B (NF-κB) and the production of proinflammatory cytokines including interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6).
Beyond its canonical role in host defense against bacterial infection, TLR4 is increasingly recognized as a central mediator of sterile inflammation across a broad spectrum of pathological conditions. Its activation drives tissue-damaging neuroinflammation in neurodegenerative and neuropathic pain states, promotes fibrosis, facilitates tumor progression and metastasis, and modulates immunophenotypic changes in circulating leukocytes exposed to environmental or pharmacological stressors. This dual role — protective in acute infection yet injurious in chronic or dysregulated contexts — makes TLR4 a high-priority research target for therapeutic intervention in inflammation-driven diseases, ranging from metabolic dysfunction–associated steatotic liver disease (MAFLD/NAFLD) to Parkinson's disease and cancer.
Where the papers sit
22 papers from the last 6 months study Toll-like receptor 4 (TLR4) directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 1 observational · 6 human data · 15 preclinical
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Inflammatory Signaling across Organs
Suppressing TLR4/MyD88/NF-κB signaling is the recurring strategy for reducing inflammation across brain injury, neurodegeneration, sepsis, viral infection and benign prostatic hyperplasia. Nanocurcumin, pentoxifylline, pioglitazone, isorhapontigenin and kaempferol-derived carbon dots are tested as pathway-modulating interventions. IL-1β, IL-6 and related cytokines accompany outcomes such as cognition, tissue injury and macrophage polarization. The work supports broad anti-inflammatory activity, but organ-specific mechanisms and clinical translation remain open.
8 papers · 36.4%
-
TLR4 Vaccine and Immune Design
Reverse vaccinology and multi-epitope designs are being paired with TLR4-active adjuvants to increase cytokine production and protective immunity. BECC, MPLA and SMNP recur as ways to strengthen influenza and antiviral responses, while de novo transmembrane proteins aim to inhibit innate signaling. Molecular dynamics, screening and experimental validation support the design pipeline. The set remains largely preclinical, with soluble TLR4 in intracerebral haemorrhage representing a biomarker direction rather than a vaccine result.
6 papers · 27.3%
-
Metabolic Inflammation and Barrier Dysfunction
Metabolic inflammation is being connected to impaired endometrial receptivity, gout, cognitive decline and intestinal barrier failure. HMGB1-driven ferroptosis and microglial inflammation recur in metabolic-syndrome-associated cognitive impairment, with NRF2-autophagy as a possible counter-regulatory pathway. Gut microbiota-derived metabolites and polysaccharides broaden the focus beyond TLR4 to systemic barrier and immune regulation. Evidence remains mainly mechanistic and preclinical, without a settled intervention.
4 papers · 18.2%
-
Others — Cancer and Tissue Injury
TLR4 is examined across cancer progression, treatment resistance, prognosis and ischemia-reperfusion injury. Cancer studies link signaling to metastasis, lymph-node involvement and p53 mutation-associated drug resistance, while renal work frames it as an injury mediator. Nanoparticles, CAR T cells and TLR agonism suggest combination strategies, but they address different biological problems. The cluster has no single therapeutic trajectory or shared endpoint.
4 papers · 18.2%
TLR4 activation can be therapeutically beneficial rather than merely a pathogenic inflammatory process
BECC-adjuvanted influenza vaccination in mice and MPLA/SMNP treatment in ART-treated people with HIV-1 found that deliberate TLR4 activation could improve outcomes. Whereas the set generally treats TLR4 signaling as a harmful pathway to inhibit, BECC TLR4 ligands enhanced influenza-specific humoral and cellular immunity and protective efficacy, while SMNP-induced TLR4-dependent cytokine production reactivated HIV-1 transcription and substantially reduced the inducible viral reservoir ex vivo. Together, these findings replace a uniformly suppressive view of TLR4 with a context-dependent one in which controlled activation can serve as an immunization or “shock-and-kill” therapeutic strategy 42218860May 42475333Jul.
TLR4 functions as a tumor-cell uptake receptor for a redox-responsive nanotherapeutic
Selenide-bridged redox-responsive nanoparticles for p53-mutant gastric cancer used TLR4 not primarily as an inflammatory signaling mediator but as a surface recognition and internalization receptor. The nanoparticles’ surface selenium groups recognized TLR4 overexpressed on tumor cells and promoted clathrin- and caveolin-mediated endocytosis, helping the prodrug nanoparticles accumulate in cancer cells and bypass limitations of passive EPR delivery. This assigns TLR4 a distinct targeting and drug-delivery role in which receptor recognition, rather than downstream inflammatory modulation, enables selective uptake of a therapeutic nanoplatform 42478957Jul.
Papers
The 22 papers from the last 6 months that study Toll-like receptor 4 (TLR4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Inflammatory Signaling across Organs (8)
- Neuroprotective Effect of Isorhapontigenin (ISO) Against LPS-Induced Neurodegenerative Condition via TLR4/RAGE-Mediated p-NF-kB Activation. Molecular neurobiology · 5 Sept 2026 PMID 42700283
- Mechanism of Kushen Tongguan Pill on benign prostatic hyperplasia: roles of TLR4/NF-κB pathway and macrophage M1 polarization. Journal of molecular histology · 4 Sept 2026 PMID 42696233
- PPARγ-Dependent Pioglitazone Treatment Suppresses Neuroinflammation and Improves Cognition in Sepsis-Associated Encephalopathy in Mice. CNS neuroscience & therapeutics · 31 Aug 2026 PMID 42669896
- AMBMP Hydrochloride Reverses STZ-Induced Alzheimer-Type Dementia Associated with Wnt/β-catenin/TLR4 Signaling. Neuromolecular medicine · 29 Aug 2026 PMID 42668333
- Pentoxifylline targets TLR4/MyD88/NF-κB signaling to ameliorate neuroinflammation and metabolic dysfunction in a rat model of chronic hypoperfusion-induced vascular cognitive impairment. Metabolic brain disease · 23 Jul 2026 PMID 42489766
- Kaempferol-derived carbon dots as antiviral nanomodulators of TLR4 signalling and redox homeostasis in African swine fever virus infection. Nanoscale · 8 Jul 2026 PMID 42417244
- Key targets and mechanisms by which gut microbiota-derived metabolites regulate Alzheimer's disease through the immune - inflammatory pathway: Based on network pharmacology and molecular docking. PloS one · 6 Jul 2026 PMID 42406869
- Nanocurcumin attenuates brain injury in rats with desert dry‑heat‑induced exertional heat stroke by suppressing TLR4/MyD88/NF‑κB signaling. Molecular medicine reports · 3 Jul 2026 PMID 42396648
TLR4 Vaccine and Immune Design (6)
- Programmed inhibition of an innate immune receptor via de novo designed transmembrane proteins. Proceedings of the National Academy of Sciences of the United States of America · 22 Sept 2026 PMID 42771506
- In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach. PloS one · 27 Aug 2026 PMID 42658892
- Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PloS one · 20 Jul 2026 PMID 42475333
- Temporal Profile of Soluble TLR4 and its Association with Intracerebral Haemorrhage Expansion. Translational stroke research · 20 Jul 2026 PMID 42474911
- Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches. International immunopharmacology · 12 Jun 2026 PMID 42284765
- BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy. Vaccine · 31 May 2026 PMID 42218860
Metabolic Inflammation and Barrier Dysfunction (4)
- HMGB1 aggravates neuronal ferroptosis and microglial inflammation in metabolic syndrome-associated cognitive impairment via the NRF2-autophagic flux axis. Molecular biomedicine · 18 Aug 2026 PMID 42608631
- Genome-wide association study identifies toll-like receptor four protein-mediated metabolic remodelling affecting gout pathogenesis. Journal of global health · 31 Jul 2026 PMID 42533613
- Hypothalamic Inflammation as a Critical Link Between Metabolic Dysfunction and Impaired Endometrial Receptivity in Obese Polycystic Ovary Syndrome. Physiological research · 17 Jul 2026 PMID 42466701
- Polygonatum sibiricum polysaccharide ameliorates intestinal barrier dysfunction in aging mice via gut microbiota-metabolite modulation and TLR4/NF-κB pathway inhibition. Phytomedicine : international journal of phytotherapy and phytopharmacology · 13 Jul 2026 PMID 42442028
Others — Cancer and Tissue Injury (4)
- The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer. Molecular biology reports · 29 Aug 2026 PMID 42667340
- Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS nano · 21 Jul 2026 PMID 42478957
- Adipose-derived mesenchymal stem cells improved acute renal failure induced by ischemia-reperfusion injury: Focusing on toll-like receptor 4 activity and endoplasmic reticulum stress response. Journal of physiology and biochemistry · 11 Jul 2026 PMID 42435285
- CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance. Cancer immunology research · 3 Jul 2026 PMID 42397032
By study type
Observational studies and case reports (1)
- Genome-wide association study identifies toll-like receptor four protein-mediated metabolic remodelling affecting gout pathogenesis. Journal of global health · 31 Jul 2026 PMID 42533613
Human data, design not indexed (6)
- Programmed inhibition of an innate immune receptor via de novo designed transmembrane proteins. Proceedings of the National Academy of Sciences of the United States of America · 22 Sept 2026 PMID 42771506
- The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer. Molecular biology reports · 29 Aug 2026 PMID 42667340
- In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach. PloS one · 27 Aug 2026 PMID 42658892
- Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PloS one · 20 Jul 2026 PMID 42475333
- Temporal Profile of Soluble TLR4 and its Association with Intracerebral Haemorrhage Expansion. Translational stroke research · 20 Jul 2026 PMID 42474911
- Key targets and mechanisms by which gut microbiota-derived metabolites regulate Alzheimer's disease through the immune - inflammatory pathway: Based on network pharmacology and molecular docking. PloS one · 6 Jul 2026 PMID 42406869
Preclinical: animal, cell and lab studies (15)
- Neuroprotective Effect of Isorhapontigenin (ISO) Against LPS-Induced Neurodegenerative Condition via TLR4/RAGE-Mediated p-NF-kB Activation. Molecular neurobiology · 5 Sept 2026 PMID 42700283
- Mechanism of Kushen Tongguan Pill on benign prostatic hyperplasia: roles of TLR4/NF-κB pathway and macrophage M1 polarization. Journal of molecular histology · 4 Sept 2026 PMID 42696233
- PPARγ-Dependent Pioglitazone Treatment Suppresses Neuroinflammation and Improves Cognition in Sepsis-Associated Encephalopathy in Mice. CNS neuroscience & therapeutics · 31 Aug 2026 PMID 42669896
- AMBMP Hydrochloride Reverses STZ-Induced Alzheimer-Type Dementia Associated with Wnt/β-catenin/TLR4 Signaling. Neuromolecular medicine · 29 Aug 2026 PMID 42668333
- HMGB1 aggravates neuronal ferroptosis and microglial inflammation in metabolic syndrome-associated cognitive impairment via the NRF2-autophagic flux axis. Molecular biomedicine · 18 Aug 2026 PMID 42608631
- Pentoxifylline targets TLR4/MyD88/NF-κB signaling to ameliorate neuroinflammation and metabolic dysfunction in a rat model of chronic hypoperfusion-induced vascular cognitive impairment. Metabolic brain disease · 23 Jul 2026 PMID 42489766
- Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS nano · 21 Jul 2026 PMID 42478957
- Hypothalamic Inflammation as a Critical Link Between Metabolic Dysfunction and Impaired Endometrial Receptivity in Obese Polycystic Ovary Syndrome. Physiological research · 17 Jul 2026 PMID 42466701
- Polygonatum sibiricum polysaccharide ameliorates intestinal barrier dysfunction in aging mice via gut microbiota-metabolite modulation and TLR4/NF-κB pathway inhibition. Phytomedicine : international journal of phytotherapy and phytopharmacology · 13 Jul 2026 PMID 42442028
- Adipose-derived mesenchymal stem cells improved acute renal failure induced by ischemia-reperfusion injury: Focusing on toll-like receptor 4 activity and endoplasmic reticulum stress response. Journal of physiology and biochemistry · 11 Jul 2026 PMID 42435285
- Kaempferol-derived carbon dots as antiviral nanomodulators of TLR4 signalling and redox homeostasis in African swine fever virus infection. Nanoscale · 8 Jul 2026 PMID 42417244
- CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance. Cancer immunology research · 3 Jul 2026 PMID 42397032
- Nanocurcumin attenuates brain injury in rats with desert dry‑heat‑induced exertional heat stroke by suppressing TLR4/MyD88/NF‑κB signaling. Molecular medicine reports · 3 Jul 2026 PMID 42396648
- Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches. International immunopharmacology · 12 Jun 2026 PMID 42284765
- BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy. Vaccine · 31 May 2026 PMID 42218860
Written from 22 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.